Spark Therapeutics, Inc. (ONCE) Insider Barge Joseph La Sells 5,500 Shares

Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 5,500 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.44, for a total value of $392,920.00. Following the transaction, the insider now owns 8,146 shares of the company’s stock, valued at $581,950.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Barge Joseph La also recently made the following trade(s):

  • On Thursday, November 9th, Barge Joseph La sold 3,309 shares of Spark Therapeutics stock. The stock was sold at an average price of $71.31, for a total value of $235,964.79.
  • On Tuesday, September 5th, Barge Joseph La sold 5,500 shares of Spark Therapeutics stock. The stock was sold at an average price of $81.00, for a total value of $445,500.00.

Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at $72.65 on Tuesday. Spark Therapeutics, Inc. has a 52-week low of $47.03 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same period in the previous year, the business earned ($1.07) earnings per share. The business’s quarterly revenue was up 45.8% on a year-over-year basis. equities analysts expect that Spark Therapeutics, Inc. will post -7.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/14/spark-therapeutics-inc-once-insider-barge-joseph-la-sells-5500-shares.html.

A number of research analysts recently issued reports on ONCE shares. Cantor Fitzgerald reiterated a “buy” rating and set a $105.00 price objective (up from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a report on Friday, October 6th. Barclays PLC increased their price objective on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Cowen and Company reiterated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Chardan Capital reiterated a “buy” rating and set a $100.00 price objective on shares of Spark Therapeutics in a report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have given a buy rating to the stock. Spark Therapeutics presently has a consensus rating of “Buy” and an average target price of $90.36.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its position in shares of Spark Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after buying an additional 122 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in Spark Therapeutics by 3.2% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 342 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the last quarter. KCG Holdings Inc. lifted its holdings in Spark Therapeutics by 9.4% during the 1st quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 538 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in Spark Therapeutics by 1.9% during the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after purchasing an additional 650 shares during the last quarter. 77.94% of the stock is owned by institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply